Harmony Biosciences Holdings, Inc. (HRMY)


Stock Price Forecast

April 16, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Harmony Biosciences Holdings, Inc. chart...

About the Company

We do not have any company description for Harmony Biosciences Holdings, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

221

Exchange

Nasdaq

$679M

Total Revenue

221

Employees

$2B

Market Capitalization

13.37

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $HRMY News

Harmony Biosciences Secures Exclusive Rights to Promising Narcolepsy Treatment

3d ago, source: MyChesCo on MSN

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), in a strategic move to bolster its portfolio in sleep/wake disorders, has ...

Harmony Biosciences Holdings Inc.

1d ago, source: Wall Street Journal

1 Day HRMY 1.98% DJIA -0.49% S&P Mid Cap 400 -0.09% Health Care/Life Sciences -0.55% ...

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 R…

7d ago, source:

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, ...

Harmony Biosciences Holdings Inc's Chief Commercial Officer Sells Company Shares

1mon ago, source: Yahoo Finance

On the valuation front, Harmony Biosciences Holdings Inc's shares were trading at $32 on the day of the insider's recent sale, giving the company a market cap of $1.793 billion. The price-earnings ...

Harmony inks licensing deal for sleep disorder therapy

7d ago, source: Seeking Alpha on MSN

Harmony Biosciences (NASDAQ:HRMY) announced a licensing agreement with Paris-based biopharma company Bioprojet on Thursday to ...

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

15d ago, source: Stockhouse

PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate ...

Harmony Biosciences Holdings Inc Ordinary Shares

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Harmony Biosciences Holdings Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Harmony Biosciences Holdings Inc.

24d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...